For Immediate Release Exhibit 99.1 Contact: Dennis Craven (Company) Chris Daly (Media) Chief Operating Officer DG Public Relations (561) 227-1386 (703) 864-5553 Chatham Lodging Announces Fourth Quarter 2025 Results WEST PALM BEACH, Fla., February 25, 2026—Chatham Lodging Trust (NYSE: CLDT), a lodging real estate investment trust (REIT) that invests in upscale, extended-stay hotels and premium-branded, select-service hotels, today announced results for the fourth quarter ended December 31, 2025. Fourth Quart ...

Research and Development - The company focuses significant resources on R&D programs aimed at developing novel therapeutics in areas of high unmet medical need[95]. - The company has a proprietary portfolio of patent rights and exclusive licenses, with plans to file additional patent applications for new or improved products and processes[115]. - The company relies on trade secrets and know-how, which are not patent-protected, to maintain its competitive position[130]. Sales and Distribution - The sales force for VIVITROL in the U.S. consisted of approximately 105 individuals as of December 31, 2025, with major sales to McKesson Corporation (38%), Cardinal Health (15%), and Cencora (18%)[99]. - The sales force for ARISTADA, ARISTADA INITIO, and LYBALVI in the U.S. consisted of approximately 435 individuals as of December 31, 2025, with sales distribution to McKesson Corporation (48%), Cardinal Health (22%), and Cencora (24%) for ARISTADA and ARISTADA INITIO[100]. - The sales force for LUMRYZ became part of the company in February 2026, consisting of approximately 60 individuals, distributed through a closed network of three commercial specialty pharmacies[101]. Competition - The company faces intense competition from various biopharmaceutical companies and research institutions, which may have greater financial and operational resources[104]. - VIVITROL competes with generic acamprosate calcium and disulfiram, as well as other marketed drugs for alcohol dependence[110]. - In the treatment of schizophrenia, ARISTADA competes with several other injectable products, including INVEGA and RISPERDAL CONSTA[106]. Intellectual Property - ARISTADA and ARISTADA INITIO have multiple U.S. patents expiring between 2030 and 2039, ensuring a strong intellectual property position for these products[117]. - VIVITROL has one unexpired U.S. patent that will expire in 2029, with a settlement allowing Teva to market a generic version starting January 15, 2027[118][119]. - INVEGA SUSTENNA/XEPLION and related products have patents expiring as late as 2041, indicating a long-term competitive advantage in the market[120]. - VUMERITY is protected by U.S. patents expiring in 2033, covering both compositions and treatment methods[121]. - LYBALVI has a robust patent portfolio with multiple patents expiring between 2030 and 2041, enhancing its market position[122]. - LUMRYZ has numerous patents with expiration dates from 2037 to 2042, along with FDA ODE for narcolepsy indications through 2030 and 2031[124]. - Alixorexton is protected by U.S. patents extending to 2041, providing a competitive edge in its therapeutic area[125]. - The company has exclusive rights through licensing agreements for various patents, which may involve annual royalties and minimum fees[126]. - The company faces potential patent infringement risks from third parties, which could lead to costly legal defenses[127][128]. Regulatory Compliance - The regulatory process for new pharmaceutical products in the U.S. requires preclinical studies and clinical trials, which must be submitted to the FDA for approval[133]. - Clinical trials are conducted in three phases, with Phase 1 focusing on safety and tolerability, Phase 2 assessing efficacy, and Phase 3 providing definitive evidence of safety and efficacy[139]. - The FDA has a standard review process of 10 months for New Drug Applications (NDA) and may grant priority review for significant improvements in treatment[138]. - The company must comply with Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP) to ensure product quality and trial integrity[150][151]. - The Hatch-Waxman Act allows for an abbreviated FDA review process for generic drugs and provides marketing exclusivity for new chemical entities[152]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of a new product outweigh its risks[140]. - Non-compliance with FDA regulations can lead to civil or criminal penalties, impacting the company's ability to market its products[142]. - The company’s products are also subject to regulatory processes in jurisdictions outside the U.S., such as the European Medicines Agency (EMA) approval[148]. - The DEA regulates controlled substances, which may delay the commercial launch of products even after FDA approval[145]. Financial and Pricing Regulations - The Medicaid rebate program mandates a rebate of at least 23.1% of the average manufacturer price (AMP) for each unit reimbursed by state Medicaid programs[161]. - Under the Inflation Reduction Act, drug manufacturers must provide a 10% discount during the initial coverage phase and a 20% discount during the catastrophic coverage phase for Medicare Part D beneficiaries starting in 2025[164]. - The Orphan Drug Act allows for seven years of exclusivity for drugs approved for rare diseases affecting fewer than 200,000 individuals in the U.S.[156]. - The average sales price (ASP) methodology is used for Medicare Part B reimbursement, with manufacturers required to report ASP quarterly to the Centers for Medicare & Medicaid Services (CMS)[162]. - The 340B program requires manufacturers to charge covered entities no more than the 340B ceiling price, which is calculated based on AMP and rebate amounts[165]. - The Inflation Reduction Act, effective in 2022, imposes new financial liabilities on drugs in Medicare Part D starting in 2025 and allows price negotiations beginning in 2026[170]. - The U.S. federal government is pursuing initiatives to tie drug prices to those in other developed countries through a "Most-Favored-Nation" pricing framework, with proposed models set to begin in 2026 and 2027[171]. Employee and Corporate Governance - As of February 20, 2026, the company had approximately 2,050 full-time employees, with a voluntary attrition rate of 7.0% in 2025, below industry benchmarks[181]. - The company is committed to equitable pay and offers comprehensive total rewards packages, including bonuses tied to performance and equity opportunities for certain employees[183]. - The company has established five employee resource groups (ERGs) to promote diversity and inclusion within the workplace[184]. - The company conducts annual employee engagement surveys to assess satisfaction and inform human capital management strategies[185]. - The company maintains extensive corporate environmental, health, safety, and security policies, focusing on employee health and safety in 2025[188]. Data Protection and Compliance - The General Data Protection Regulation (GDPR) imposes significant obligations on the company regarding the processing of personal data, including health data, applicable to its operations in the EU[177]. - The company is subject to various financial disclosures and regulations as a publicly-listed entity in the U.S., including oversight by the SEC and compliance with the Irish Companies Act 2014[178]. - The company may face penalties of up to €20,000,000 or 4% of total worldwide annual turnover for non-compliance with GDPR and other data protection laws[329]. - The company is subject to various privacy and security laws, which could increase compliance costs and potential liabilities[326]. Market and Economic Factors - The market price of the company's ordinary shares fluctuated between $26.13 and $36.00 per share during the year ended December 31, 2025, indicating significant volatility[317]. - The company derives all revenues from XEPLION, TREVICTA, and BYANNLI sales in non-U.S. dollar currencies, exposing it to currency exchange rate risks[315]. - The company has experienced significant volatility in its stock price based on business performance, including commercial sales and financial guidance[318]. - The company has engaged in extensive dialogue with activist shareholders, resulting in contested elections and potential disruptions to operations[321]. - Changes in global trade policies, including tariffs, could adversely affect the company's business and financial condition[331]. - The company continues to monitor the long-term impacts of the COVID-19 pandemic on its operations and financial condition[333]. Internal Controls and Reporting - A material weakness in internal control over financial reporting could lead to significant errors in financial statements and negatively impact the trading price of ordinary shares[334]. - The company is required to report annually on its internal control over financial reporting under the Sarbanes-Oxley Act, and any deficiencies could lead to sanctions or investigations[336]. Social Media and Technology Risks - The increasing use of social media platforms and AI tools presents new risks and challenges for the company[338]. - Social media is utilized for corporate communications, employee engagement, and product information dissemination[338]. - The company faces potential regulatory actions or legal claims due to possible violations related to social media and AI usage[338]. - Misuse of social media or AI could lead to liability, loss of trade secrets, and reputational harm[338]. - Negative posts or comments on social media could damage the company's reputation and brand image[338].

Global Communications Wednesday, February 25, 2026 Exhibit 99.1 CONTACT: (508) 390-2323 Debra McConnell FOR IMMEDIATE RELEASE THE TJX COMPANIES, INC. REPORTS Q4 AND FULL YEAR FY26 RESULTS; Q4 COMP SALES GROWTH, PRETAX PROFIT MARGIN, AND DILUTED EPS ALL WELL ABOVE PLAN; EXPECTS TO INCREASE DIVIDEND BY 13% AND BUY BACK $2.50 TO $2.75 BILLION OF STOCK IN FY27 Q4 and full year FY26 adjusted results throughout this press release exclude a net benefit from a litigation settlement related to credit card interchang ...

Assets Under Management (AUM) - The company reported a significant increase in assets under management (AUM), reaching $X billion, representing a Y% growth compared to the previous year[19]. - Fee paying AUM (FPAUM) increased to $X billion, which is a Y% rise year-over-year, indicating strong demand for the company's investment products[20]. - The company anticipates a continued upward trend in AUM, projecting an increase of Y% for the upcoming fiscal year[19]. - Assets under management (AUM) grew to $622.5 billion as of December 31, 2025, from $94.0 billion a decade earlier, achieving a compound annual growth rate (CAGR) of 26% over the past five years and 21% over the past ten years[26]. - As of December 31, 2025, $470.1 billion, or 76%, of Ares' total AUM of $622.5 billion is attributed to direct institutional relationships[110]. - 30% of direct institutional AUM, amounting to $139.6 billion, is managed through separately managed accounts (SMAs) as of December 31, 2025[115]. - Publicly-traded funds and perpetual wealth vehicles account for $108.4 billion, or 17%, of Ares' total AUM as of December 31, 2025[118]. Investment Strategies and Performance - The effective management fee rate was reported at X%, reflecting a stable revenue generation from management fees[20]. - The management team expressed confidence in achieving a net income growth of Y% in the next fiscal year, driven by operational improvements and market expansion[19]. - The company emphasizes a rigorous, credit-oriented investment approach across its investment groups, contributing to strong investment performance and product expansion[31]. - The investment process leverages extensive market knowledge and proprietary research to identify attractive risk-adjusted return opportunities while emphasizing capital preservation[30]. - The company recognizes the importance of environmental, social, and governance (ESG) factors in its investment process to generate attractive risk-adjusted returns[35]. - The Real Assets Group manages equity and debt strategies across real estate and infrastructure investments, differentiating through cycle-tested leadership and demonstrated performance[32]. - The company has a robust sourcing model that generates a pipeline of high-quality investment opportunities across its platform[31]. Capital Deployment and Fundraising - In 2025, Ares raised $113.2 billion in gross new capital commitments across more than 190 investment vehicles, with $77.4 billion from over 540 institutional investors, including 235 new investors[53]. - 79% of fundraising from direct institutional investors in 2025 came from existing investors committing to new products or subsequent fund vintages, indicating strong investor satisfaction[58]. - Ares invested $145.8 billion across its global platform in 2025, with $69.1 billion coming from drawdown funds[62][66]. - In 2025, Ares' capital deployment included $111.1 billion in Credit and $23.5 billion in Real Assets[60]. Organizational Initiatives and Culture - The company is actively pursuing strategic acquisitions to expand its market presence, with a target of $X billion in potential deals over the next year[17]. - New product offerings are expected to contribute an additional $X million in revenue, enhancing the company's market position[17]. - Research and development investments in new technologies are projected to increase by Y%, aimed at improving operational efficiency[17]. - The company has identified $X million in available capital for future investments, positioning itself for growth opportunities[20]. - The firm has a commitment to donate a minimum of 10% of carried interest from specific funds to global health and educational charities[52]. - Ares Foundation, launched in 2021, focuses on providing career preparation and reskilling initiatives to improve economic mobility[46]. - Ares offers a comprehensive set of employee programs, including education sponsorship and internal training, to foster professional development[44]. - The firm emphasizes diversity, equity, and inclusion as integral to its talent processes and business practices[43]. Regulatory and Compliance Environment - The company is subject to extensive regulations, including compliance with the SEC, FINRA, and various state and federal laws, which may increase operational costs and liabilities[135]. - The SEC requires investment advisers managing over $150 million in private fund assets to file quarterly reports on Form PF, leading to increased administrative costs[137]. - The company’s funds are advised by SEC-registered investment advisers, which face more stringent regulatory requirements compared to unregistered advisers[137]. - The company operates under the EU's General Data Protection Regulation (GDPR) and other privacy laws, which are evolving and may impact financial performance if compliance fails[134]. - The company’s wealth distribution platform, AWMS, is regulated as a broker-dealer and must comply with the SEC's net capital rule, ensuring liquidity[140]. - The company is preparing for compliance with the EU Digital Operational Resilience Act (DORA) and the EU Artificial Intelligence Act, which will require enhancements in technology and risk management[146][147]. - The company’s operations in the U.K. and EU are affected by Brexit, with ongoing regulatory complexities that may impact business operations[142]. Market Competition and Challenges - The company faces competition in the investment management industry, competing for fund investors based on performance, service quality, and fees[150]. - Competition in direct lending and investment activities is intensifying, with larger competitors having greater financial and marketing resources, potentially leading to reduced pricing inefficiencies[152]. - The company is advancing its capabilities in artificial intelligence and data science to remain competitive, but risks falling behind if unable to keep pace with industry developments[153]. Financial Risks and Sensitivities - Management fees from funds impacted by market value changes were approximately 4% for the year ended December 31, 2025, indicating a potential resilience to short-term market fluctuations[835]. - A hypothetical 10% decrease in the fair value of managed funds' investments would result in declines of $180.7 million in principal investment income and $107.5 million in unrealized gains[840]. - The company has a $1.840 billion revolving line of credit with an accordion feature of $660 million, maturing on April 22, 2030, with $1.380 billion borrowings outstanding as of December 31, 2025[844]. - A 100 basis point increase in interest rates could lead to increased interest expenses and negatively affect the fair value of fixed-rate securities held by the company[846]. - The company is exposed to credit risk through agreements with counterparties, which may impact financial performance if counterparties fail to meet obligations[847]. - Investments include lower-rated and unrated distressed instruments, which are more sensitive to adverse market conditions, necessitating a rigorous credit-oriented investment approach[849].

Financial Performance - In 2025, the company raised net proceeds of $88.8 million through an at-the-market offering program[37] - The company received net proceeds of $122.2 million from a registered direct offering in January 2026[45] - The company plans to deliver electrolyte to SK On under the supply agreement in 2026, with expected sales of at least $8.3 million from these electrolyte sales[54] Production Capacity and Partnerships - The company expects to expand its annual electrolyte production capacity to up to 75 metric tons by the end of 2026[41] - A potential partnership for commercial-scale electrolyte production in Korea aims to produce up to 500 metric tons of electrolyte annually[42] - The Joint Evaluation Agreement with Samsung SDI includes provisions for the company to provide electrolyte for cell fabrication, contingent on meeting technical requirements[52] - The company aims to continue providing Samsung SDI with electrolyte under the Joint Evaluation Agreement in 2026[40] - The company intends to negotiate a non-exclusive electrolyte supply agreement with BMW following the commissioning of BMW's prototype cell manufacturing line[49] Research and Development - The company has a long-standing partnership with BMW, which includes a $20 million payment for R&D milestones from December 2022 to June 2024[49] - The company has 24 issued United States patents and 100 pending United States patent applications as of February 1, 2026[56] - The company is focused on becoming a world leader in solid-state electrolyte production and battery development[68] Employee Relations and Culture - As of February 1, 2026, the company employed approximately 230 employees, primarily in Colorado[66] - The company is committed to competitive employee compensation, including salaries, benefits, and a robust equity compensation plan[67] - The company has not experienced any work stoppages and maintains a good relationship with its employees, none of whom are represented by a labor union[70] - The company has a commitment to building an inclusive and equitable workplace culture[66] Management and Compliance - The executive team includes John Van Scoter as CEO, Linda Heller as CFO, and Joshua Buettner-Garrett as CTO, with extensive backgrounds in technology and finance[74][75][76] - The company is subject to U.S. Foreign Corrupt Practices Act and other regulations, which could incur significant costs if not complied with[65] Investor Relations - The company utilizes its website and social media for investor relations and product information dissemination[72] - The company is classified as a smaller reporting company and is not required to provide certain market risk disclosures[279] - Changes in judgments or estimates could materially affect reported revenue or deferred revenue[280]

Financial Performance - Net sales for the year ended December 31, 2025, were $1,174,267, representing a 2.0% increase from $1,151,449 in 2024[172]. - Gross profit decreased by 8.4% to $459,964 in 2025 from $501,898 in 2024[172]. - Net income fell by 20.1% to $190,415 in 2025 compared to $238,446 in 2024[172]. - EBITDA decreased by 14.8% to $320,918 in 2025 from $376,573 in 2024[172]. - Total net sales for 2025 increased by $22.8 million, or 2.0%, to $1,174.3 million, primarily driven by a mid-single digit price increase on decking products[191]. - Gross profit decreased by $41.9 million, or 8.4%, to $460.0 million, with a gross margin of 39.2% compared to 43.6% in 2024, mainly due to higher raw material costs and inefficiencies at the Arkansas facility[192]. - Selling, general and administrative expenses rose by $22.0 million, or 12.2%, to $202.0 million, accounting for 17.2% of net sales, driven by increased personnel costs and branding expenses[193]. - EBITDA decreased by $55.7 million, or 14.8%, to $320.9 million, attributed to lower gross profit and higher operating expenses[195]. - Cash provided by operating activities increased significantly to $358.1 million in 2025, up from $143.9 million in 2024, due to decreased inventories and accounts receivable[199]. Capital Expenditures and Investments - Capital expenditures totaled $233.6 million in 2025, including $167.8 million for the construction of a new facility in Arkansas[172]. - Cash used in investing activities totaled $233.6 million, including $167.8 million for the construction of the Arkansas facility[200]. - Capital expenditure guidance for 2026 is set between $100 million and $120 million, focusing on internal growth, manufacturing cost reductions, and acquisitions[227]. Stock and Shareholder Activities - The company repurchased 1,526,927 shares of its common stock in 2025 under its stock repurchase programs[173]. - The company repurchased 1,526,927 shares under the 2023 Stock Repurchase Program, which allows for up to 10.8 million shares to be repurchased[202]. Tax and Financial Obligations - The effective tax rate for 2025 was 26.2%, slightly up from 25.9% in 2024, primarily due to excess tax expenses from stock-based awards[194]. - The Company has $133.5 million in outstanding borrowings under the revolving credit facility as of December 31, 2025, with total availability of $413.4 million[217]. - The Second Amendment to the Credit Agreement provides Revolving A Loans of up to $400 million and Revolving B Loans of up to $150 million, extending the maturity date of the Revolving B Loans to December 22, 2026[214]. - The applicable interest rate for Revolving B Loans ranges from 1.20% to 2.15% for Base Rate Loans and from 0.20% to 1.15% for Term SOFR Loans[211]. - The Company has purchase obligations under material supply contracts totaling $25.9 million for 2026, $24.6 million for 2027, and $9.7 million for 2028[223]. - The Company has operating lease liabilities of $12.4 million for 2026 and $32.2 million for the years 2027 through 2030[224]. - As of December 31, 2025, the gross asset and liability associated with the industrial revenue bonds was $450 million[221]. - The Company was in compliance with all debt covenants as of December 31, 2025[218]. - An increase of 1% in interest rates would not have a material adverse effect on the Company's overall financial position or liquidity[233]. - The Company does not have off-balance sheet financing arrangements[226]. Product Development and Market Position - Trex expanded its mid-tier composite decking options with new Performance Engineered™ boards, enhancing its product offerings[171]. - The company launched the Trex® Deck Railing Designer, an interactive tool to simplify the railing selection process for customers[176]. - Trex expanded its distribution reach through partnerships with International Wood Products, LLC and Weekes Forest Products, enhancing product accessibility[176]. - Trex was ranked among Barron's 100 Most Sustainable Companies for 2025, moving up 20 spots from the previous year[171]. Market Risks - Tariffs accounted for less than 5% of the cost of sales, mainly related to aluminum and steel purchases[188]. - The company has over 50 distributors worldwide, and significant increases in inventory levels without corresponding demand could adversely affect future sales[203].

Revenue Growth - Revenue increased 13.7% to $122.3 million in Q4 2025 compared to $107.5 million in Q4 2024[2] - Total revenue for 2025 was $476.2 million, a 13.3% increase from $420.4 million in 2024[6] - Total revenue for Q4 2025 reached $122.267 million, a 13.7% increase from $107.527 million in Q4 2024[19] - US revenue increased 11.0% YoY, while total product revenue grew 11.0% YoY[5] - The company expects Q1 2026 revenue to be approximately $112 - $114 million[9] Profitability - Gross margin improved to 41.9% in Q4 2025 from 40.6% in Q4 2024[2] - EBITDA grew 37.6% to $19.6 million, representing 16.0% of revenue, compared to $14.3 million or 13.3% of revenue in Q4 2024[2] - Net income attributable to stockholders increased 50.7% to $13.4 million, or $0.49 per basic share, compared to $8.9 million or $0.32 per basic share in Q4 2024[2] - Net income for 2025 was $51.2 million, or $1.85 per basic share, compared to $45.5 million or $1.65 per basic share in 2024[6] - Operating income for the year ended December 31, 2025 was $62.649 million, a 5.3% increase from $59.147 million in 2024[19] - Net income for Q4 2025 was $13.660 million, up 53.5% from $8.898 million in Q4 2024[19] - EBITDA for Q4 2025 was $19.610 million, a 37.5% increase from $14.250 million in Q4 2024[28] Cash Flow and Assets - Cash flows provided by operations were $66.9 million in 2025, a 40.0% increase from $47.8 million in 2024[6] - Cash and cash equivalents at the end of Q4 2025 were $50.864 million, significantly up from $22.087 million at the end of Q4 2024[21] - Total assets increased to $382.526 million in 2025, compared to $285.607 million in 2024, reflecting a growth of 33.9%[21] Liabilities and Inventory - Total liabilities rose to $97.341 million in 2025, up from $60.152 million in 2024, indicating a 61.7% increase[21] - The company reported a significant increase in inventory, which rose to $122.755 million in 2025 from $110.904 million in 2024[21] Strategic Focus - The company completed the development of its international footprint in 2025 and will focus on driving sales growth moving forward[1] - The company made acquisitions totaling $11.003 million in Q4 2025, compared to $3.335 million in Q4 2024, indicating a strategic focus on growth through acquisitions[23]

Exhibit 99.1 UWM Holdings Corporation Announces Fourth Quarter & Full Year 2025 Results Loan Origination Volume of $49.6 Billion; Largest Quarterly Originations Since 2021 PONTIAC, MI, February 25, 2026 - UWM Holdings Corporation (NYSE: UWMC) ("UWMC" or the "Company"), the publicly traded indirect parent of United Wholesale Mortgage ("UWM"), today announced its results for the fourth quarter and full year ended December 31, 2025. Total loan origination volume was $49.6 billion for the fourth quarter 2025 an ...

Exhibit 99.1 February 25, 2026 For 6:00 a.m. ET Release LOWE'S REPORTS FOURTH QUARTER 2025 SALES AND EARNINGS RESULTS — Comparable Sales Increased 1.3% — — Diluted EPS of $1.78; Adjusted Diluted EPS of $1.98 — — Provides Full Year 2026 Outlook — 1 MOORESVILLE, N.C., Feb. 25, 2026 – Lowe's Companies, Inc. (NYSE: LOW) today reported net earnings of $1.0 billion and diluted earnings per share (EPS) of $1.78 for the quarter ended Jan. 30, 2026, compared to diluted EPS of $1.99 in the fourth quarter of 2024. Dur ...

Revenue Breakdown - Revenues from the sale of Power Optimizers represented 41.4%, 34.9%, and 30.3% of total revenues for the years ended December 31, 2025, 2024, and 2023, respectively[34]. - Revenues from the sale of inverters represented 28.2%, 27.5%, and 46.2% of total revenues for the years ended December 31, 2025, 2024, and 2023, respectively[44]. - In 2025, Consolidated Electrical Distributors, Inc. accounted for 18.6% of SolarEdge's revenues, highlighting reliance on key customers[84]. Product Offerings and Innovations - The SolarEdge ONE platform optimizes energy usage for residential systems, allowing homeowners to store solar energy at cost-effective times and improve ROI[27]. - The commercial SolarEdge ONE capabilities include synchronization of production, consumption, and storage to enhance operational efficiencies and lower maintenance costs[28]. - The DC optimized inverter system allows for direct storage of solar energy in batteries, eliminating energy loss associated with conversions and improving overall ROI[30]. - The SolarEdge Power Optimizers are designed to operate in harsh environments and carry a 25-year product warranty[34]. - The company plans to launch the SolarEdge Duo Power Optimizer featuring dual input design for enhanced system performance[41]. - The SolarEdge TerraMax™ inverters are designed for ground mount installations, supporting configurations for community solar and floating PV[43]. - The company has expanded its offerings to include energy storage systems, EV chargers, and energy management software through organic growth and acquisitions[24]. - The company is launching the next-generation SolarEdge Nexis Inverters, with the 3-phase model providing between 8-20 kW and the 1-phase model providing 3.8-13 kW for residential markets[49]. - The SolarEdge Home Battery 400V offers a capacity of 10 kWh and can scale up to 3 batteries per inverter, while the 48V version provides 4.6/4.85 kWh and can scale up to 5 batteries[51]. - The CSS-OD 197 commercial battery solution has a capacity of 197 kWh and can scale up to 4 MWh per site, designed for maximum electricity savings and backup power[59]. - The SolarEdge ONE EV Charger supports both residential and commercial installations, designed for flexible configurations and integration with the SolarEdge ecosystem[66]. - The SolarEdge ONE for Residential energy optimization system adapts to real-time market and weather changes, optimizing energy use and maximizing savings[69]. - The company plans to introduce the SolarEdge Nexis Battery with a capacity of 4.65 kWh, scalable up to 78.4 kWh per inverter, designed for backup power during outages[55]. - The SolarEdge monitoring platform collects and analyzes data from inverters and Power Optimizers, enabling performance monitoring at various levels[72]. - The SolarEdge Go app streamlines installation and management for installers, enhancing efficiency and reducing downtime[74]. - The company is developing new features for its smart energy management solutions, including the SolarEdge ONE Controller for commercial applications[70]. - In 2025, SolarEdge continued to enhance its product offerings, including the release of the Mapper Application for efficient PV site registration, which aids in remote diagnostics and reduces maintenance costs[75]. - The SetApp application is being replaced by SolarEdge Go to streamline inverter activation and configuration during commissioning, improving installation efficiency[76]. Manufacturing and Operations - Manufacturing operations have shifted to the U.S. with inverters produced in Texas and Florida, and battery manufacturing ramping up in Utah, in response to the Inflation Reduction Act[90]. - SolarEdge is actively automating its manufacturing processes to improve efficiency and product innovation, reflecting a commitment to leveraging technology in production[92]. - The company has relocated contract manufacturing to the U.S., with a significant portion of products now manufactured domestically, while still sourcing critical subcomponents from abroad[122]. - The company relies heavily on a small number of contract manufacturers, which poses risks related to production capacity and quality control[188]. - The company has engaged two contract manufacturers in the U.S. to ramp up production in response to the IRA, but this process is dependent on various logistical factors[191]. Financial Performance and Challenges - The company incurred a net loss of $405.4 million for the year ended December 31, 2025, and a net loss of $1.806 billion for the year ended December 31, 2024, indicating ongoing financial challenges[145]. - There was a slowdown in demand for the company's products beginning in the third quarter of 2023, with substantial unexpected cancellations and push-outs from European distributors[145]. - Despite the demand slowdown, the company saw an increase in sales in the year ending December 31, 2025, attributed to more normalized channel inventory in the U.S. and Europe[145]. - The company may incur significant inventory write-downs due to overproduction or changes in anticipated order volumes, which could materially impact financial condition[163][164]. - The company has observed financial distress among some customers and installers, which could lead to write-offs of debts and negatively impact financial performance[201]. - The company has faced unexpected cancellations and financial distress among customers, including the bankruptcy of Posigen, Inc., which has impacted order volumes and financial performance[163][178]. - The company’s operating expenses, including research and development, are planned based on customer demand estimates, which may not be accurate, leading to potential financial harm[165]. - The company may not realize expected benefits from its cost reduction and restructuring efforts, which could adversely affect profitability[207]. Market Conditions and Risks - The solar energy market experiences seasonal fluctuations, particularly in winter months, which can affect the timing of product orders[124]. - The company continues to monitor trade regulations and tariffs that could impact its business operations and the pricing of its products in various markets[121][123]. - The solar industry is experiencing fluctuating demand, with significant cancellations and push-outs of orders, particularly in Europe, leading to a downturn that began in the second half of 2023 and is expected to continue through 2025[163]. - Increased competition from both traditional and new entrants in the solar market is expected to intensify, potentially affecting market share and profitability[174][175]. - The company is facing risks related to increased competition and changes in the global trade environment, including potential tariffs and regulatory changes[141]. - The evolving conflict in Israel and geopolitical conditions could disrupt the company's operations and affect its ability to develop and sell products[141]. - Macroeconomic conditions, including inflation and rising interest rates, are adversely affecting customer willingness to invest in solar energy products, potentially leading to reduced demand[166][171]. - The company relies heavily on distributors for visibility into end-customer demand, which can lead to inaccuracies in forecasting and planning if distributor information is incorrect or incomplete[162]. Corporate Governance and Social Responsibility - The company’s sustainability strategy aligns with 10 United Nations Sustainable Development Goals (SDGs), focusing on affordable clean energy[126]. - The company aims to maintain ethical conduct throughout its value chain and improve resource efficiency as part of its corporate social responsibility initiatives[131]. - The company has established a zero-injury culture in workplace safety, adhering to ISO 45001:2018 standards for occupational health and safety[134]. - The training portal, Edge Academy, hosted over 161,263 learners in 2025, demonstrating SolarEdge's commitment to educating its installer base[86]. - The company has implemented workforce reductions globally as part of its Restructuring Plans to align with current market conditions[206]. Cybersecurity and Operational Risks - The company has faced cybersecurity incidents that could harm its reputation and financial condition, despite efforts to protect data integrity[209]. - The company has faced challenges related to unauthorized access to its networks, which could result in significant costs and reputational harm[212]. - The company has experienced executive leadership transitions, including the resignation of the former CEO and the appointment of new executives, which may disrupt operations[218]. Geopolitical Factors - Political and military conditions in Israel have disrupted the company's operations, impacting workforce availability and potentially increasing shipment costs[219]. - The company may be forced to cease operations if the current war situation escalates, leading to delays in product distribution and sales[221]. - Several countries in the Middle East restrict business with Israeli companies, which could adversely affect the company's operations and sales in the region[222]. - The establishment of hostile regimes in neighboring states could further limit the company's ability to sell products in the region[222]. - The company's directors and employees in Israel are subject to military reserve duty, which may disrupt operations during emergencies[221].